Ann: PanCO Clinical Study on OncoSil Published in ESMO Open, page-7

You can also pick one line out of the book and jump on the conclusion. But my question will remain with the management why they can sell it to NZ customer but have not managed to do it in UK. Covid should not be the reason that is what I am assuming again but company had used Covid as a reason in past. certainly 15.2 vs 15.5 months that you mentioned isn't the reason as well in my opinion.

I also picked on para from the document and as stated the aim here is to increase number of people who are able to do surgery for further increase their chances of survival or disease free period... IMO.

Yes, the study size is significantly low to make any conclusion and thanks to the previous board who wasted time and money behind small study... IMO.

The aim of combining ³²P-based brachytherapy with radiosensitising chemotherapy agents is to maximize the antitumoural effects in shrinking the pancreatic tumours, overall and away from the involved vessels, as well as sterilizing the surgical margins in order to increase the rate of surgical resection and the proportion with R0 margins, and minimize the risk of local recurrence. There is evidence in pancreatic cancer surgery that clear/R0 margins are associated with improved survival compared with R1 margins,

³⁷

and patients undergoing surgical resection had significantly better survival than patients who did not (median OS 35.3 months versus 16.3 months, respectively).

³⁸